This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

US FTC's Chopra criticizes agency's approach to pharmaceutical mergers

( May 11, 2021, 22:31 GMT | Official Statement) -- MLex Summary: US Federal Trade Commission member Rohit Chopra said the agency’s pro-merger approach to the pharmaceutical industry isn't sensible and FTC lacks a sound empirical basis for assuming that mergers have no impact on innovation. Chopra issued a statement regarding the FTC’s review of its pharmaceutical enforcement program, arguing for more robust investigations covering the full range of anticompetitive effects of mergers. “Oddly, Commissioners are willing to devote more resources to investigate small-time scams than to pharmaceutical megamergers,” he said.See document below. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections